Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03721757
Other study ID # C0947
Secondary ID 2017-005015-13IS
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date May 10, 2019
Est. completion date November 2023

Study information

Verified date July 2020
Source The Clatterbridge Cancer Centre NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is to investigate the use of nivolumab in sequence with standard of care surgery and radiation/chemoradiation in locally advanced oral cavity Squamous cell carcinoma of the oral cavity.


Description:

Squamous cell carcinoma of the oral cavity is usually treated with surgery, often followed by radiation therapy with or without chemotherapy. Unfortunately despite this treatment, it recurs or spreads in about half of patients. In this trial the investigators aim to investigate the use of nivolumab in sequence with standard of care surgery and radiation/chemoradiation. Following confirmation of eligibility patients will be treated with a single dose of nivolumab 1-2 weeks prior to surgery to remove their tumour. Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria (Extra capsular spread, involved margins) will be assigned to chemoradiotherapy. A further single dose of nivolumab will be given between surgery and commencement of radiotherapy or chemoradiotherapy. Following completion of chemo/radiation, patients will commence adjuvant nivolumab, with a total of 6 doses given at 4 weekly intervals. Patients will be followed up for 12 months post surgery. The primary objectives of this trial is to determine disease free survival at 12 months post surgery and the feasibility of recruiting to both cohorts.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date November 2023
Est. primary completion date May 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility 1. Signed, written informed consent 2. Subjects must be willing and able to comply with scheduled visits and procedures 3. Histologically confirmed squamous cell carcinoma of the oral cavity, (oral tongue (anterior 2/3), gingiva/alveolus, floor of mouth, buccal sulcus, retromolar trigone, and hard palate as defined by ICD-10 codes) 4. Subjects willing to have a fresh biopsy performed, or archival tissue available from diagnostic biopsy meeting requirements set out in laboratory manual. 5. Clinically and/or radiologically staged as T1-4 N1-3 or any T3-4 N0 (unless T4 on the basis of bone invasion only). Staging based upon the AJCC/UICC TNM 8th Edition. 6. Surgery planned as primary treatment modality with patients fit for major resection ± reconstruction surgical procedure. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. 18 years or over at time of provision of consent for trial inclusion. 9. Screening laboratory values must meet the following criteria - WBC = 2000/µL - Neutrophils = 1500/uL - Platelets = 100x103/uL - Hemoglobin = 9.0 g/dL - Serum creatinine = 1.5 x ULN or calculated creatinine clearance > 40 mL/min (using the Cockcroft-Gault formula) - AST = 3.0 x ULN - ALT = 3.0 x ULN - Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0x ULN). 10. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. 11. Women must not be breastfeeding 12. WOCBP must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo approximately five half-lives. WOCBP randomized/assigned to receive nivolumab should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug. 13. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives 14. Males randomized to receive nivolumab who are sexually active with WOCBP must continue contraception for 7 months (90 days plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug. Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However they must still undergo pregnancy testing as described in these sections. Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception which have a failure rate of < 1% when used consistently and correctly Exclusion Criteria: 1. Tumours staged as T4 on the basis of bone invasion only and in the absence of nodal metastases. 2. Distant metastases detected, or suspected on imaging 3. Unfit for chemoradiotherapy, due to comorbidity. 4. Previous malignancy requiring treatment within the last 3 years (with the exception of non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, oesophageal endometrial, cervical/dysplasia, melanoma, or breast). Prior head and neck cancer within the last three years is allowed if the tumour was treated with surgery only, and did not require radiotherapy. 5. Prior head and neck radiotherapy 6. On immunosuppressive medication (including steroids at dose equivalent to prednisolone >10mg/day unless used as replacement therapy). 7. Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, lichen planus or other conditions not expected to recur in the absence of an external trigger are permitted to enrol. 8. Known human immunodeficiency virus (HIV) or viral hepatitis infection. 9. Women who are pregnant or breastfeeding 10. Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Nivolumab, Surgery, Radiotherapy
A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
Nivolumab, Surgery, Chemoradiotherapy
A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy

Locations

Country Name City State
United Kingdom Clatterbridge Cancer Centre NHS Foundation Trust Bebington

Sponsors (3)

Lead Sponsor Collaborator
The Clatterbridge Cancer Centre NHS Foundation Trust Bristol-Myers Squibb, University of Liverpool

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease free survival 1 year disease free survival defined as disease recurrence or death at 12 months from surgery Patients will be followed up for 12 months following surgery
Primary Recruitment Rate Measured as the number of patients/site/month Period of recruitment
Secondary Overall survival Overall survival measured as the time from surgery to death by any cause Patients will be followed up for 12 months following surgery
Secondary Surgical complications - Infection rate Measured as incidence of post surgical infection up to 8 weeks post date of surgery
Secondary Surgical complications - length of hospital admission Measured as length of time between admission for surgery and discharge up to 8 weeks post date of surgery
Secondary Surgical complications - free flap failure Measured as incidence of failure of free flap reconstruction up to 8 weeks post date of surgery
Secondary Surgical complications - perioperative (30-day mortality) Measured as Incidence of death post surgery by any cause up to 30 days post date of surgery
Secondary Assessment of adverse events Assessment of adverse events, adverse events recorded will be classified using CTCAE v4 Following participants informed consent up to 100 days following last dose of trial treatment.
Secondary The change of Quality of Life: EORTC QLQ-C30 v3 The change of quality of life is measured using the EORTC QLQ-C30 v3 quality of life questionnaire. The quality of life scale is transformed into a score of 0 to 100, derived by a 4-point Likert scale. A higher score represents a higher level of quality of life. Patients will be followed up for 12 months following surgery
Secondary The change of symptom The change of symptoms is measured using the EORTC quality of life questionnaire (EORTC QLQ) Head and Neck cancer module (QLQ-H&N35). The symptom scale is transformed into a score of 0 to 100, derived by a 4-point Likert scale. A higher score represents a higher level of symptom. Patients will be followed up for 12 months following surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Completed NCT02873819 - Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity Phase 2
Active, not recruiting NCT04387682 - Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients N/A
Completed NCT01321892 - Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium N/A
Completed NCT01636544 - Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity N/A
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Withdrawn NCT04831450 - Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Recruiting NCT04191460 - Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Terminated NCT01077869 - A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis Phase 1
Completed NCT02609386 - IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Phase 2
Not yet recruiting NCT05452408 - Antitumor-B KAC PK Study Phase 1
Not yet recruiting NCT03364166 - Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma N/A
Terminated NCT02331875 - Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity Phase 1/Phase 2
Completed NCT01265849 - Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03575598 - Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study Early Phase 1
Active, not recruiting NCT03459729 - Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer Early Phase 1